|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Adventrx Pharmaceuticals Inc., of San Diego, said the FDA cleared its investigational new drug application to begin a Phase Ib/IIa trial of its HIV-1 entry inhibitor, BlockAide/CR. The study will assess the drug in HIV-1-positive individuals with evidence of increasing viral load despite treatment with other antiretroviral therapy. BlockAide/CR is a synthetic 15-amino-acid peptide that mimics a portion of HIV-1 responsible for entry into the immune system cell.
o AngioGenex Inc., of New York, completed an $875,000 convertible bridge note and warrant financing led by Atypical BioVentures Fund, which is affiliated with Aurora Capital LLC. AngioGenex is developing ...